Diabetes Mellitus, Type 2
Conditions
Brief summary
To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes
Interventions
DRUGInsulin glargine
Lantus (commercial formulation, Reference): 10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh) NPH-insulin (Protaphan) (Test): 10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes mellitus of either gender as defined by the American Diabetes Association (3) for more than 6 months * BMI (as defined in Appendix A of the protocol) between 28 kg/mý and 32 kg/mý (before implementation of Amendment 1) or between 26 kg/mý and 34 kg/mý (after implementation of Amendment 1) * Having required treatment with insulin for at least 6 months * Stable glycemic control with glycohemoglobin (HbA1c) \>7.5% and \<9.5% (before implementation of Amendment 1) or \>7.0% and \<9.5% (after implementation of Amendment 1 * Fasting serum C-peptide \>0.2 pmol/mL. According to Amendment 3, five additional subjects with low (defined as less than or equal to 0.4 pmol/mL) and 5 subjects with high (defined as \>0.4 pmol/mL) fasting C-peptide were to be enrolled. * Negative pregnancy test in female subjects of childbearing potential (only for those who were not surgically sterile or who were less than 2 years postmenopausal) at the beginning of the study * No findings in medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and muscular-skeletal system) which were clinically relevant and interfering with the conduct of the study * Normal ECG, blood pressure, pulse rate and core body temperature unless the investigator considered an abnormality to be clinically irrelevant and not interfering with the conduct of the study
Exclusion criteria
* Subjects with brittle diabetes or predisposition to severe hypoglycemia, e.g. 2 or more severe hypoglycemic episodes (i.e. requiring assistance of another person) within the past year, or any hospitalization or emergency room visit due to poor diabetic control within the past 6 months * Subjects who had been treated with insulin with a total insulin dose of \>1.5 IU/kg/day * Pregnant and nursing women * Female subjects of childbearing potential (those who are not surgically sterile or who are less than 2 years postmenopausal) unwilling or unable to use reliable contraceptive measures. Reliable contraceptive measures included the following: systemic contraceptive (oral, implant, injection), diaphragm with intravaginal spermicide, cervical cap, intrauterine device, or condom with spermicide. * Any condition requiring the regular use of any medication if the regular use of this medication interfered with the study conduct * Abuse of alcoholic beverages (as defined in Appendix B of the protocol) * Treatment with oral antidiabetic drugs within the last 4 weeks * Treatment in the previous 3 months with any drug known to have a well-defined potential for toxicity concerning vital organs * Symptoms of any major internal medical disease in the 4 weeks before the study which, according to the investigator's opinion, could interfere with the purposes of the study * History of hypersensitivity to any drugs that have a similar chemical structure to the study drug * History or presence of gastrointestinal, liver, or kidney disease or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs * Blood donation during the previous 3 months * Positive HIV- or hepatitis B/C-test * Progressive fatal disease The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes | during the study conduct |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the effect of insulin glargine (LantusT) and NPH-insulin (ProtaphanT) on suppression of endogenous glucose production, endogenous insulin secretion, and lipolysis | during the study conduct |
Outcome results
None listed